Determination of phospholipidosis potential based on gene expression analysis in HepG2 cells

Toxicological Sciences

Volumn 96, Issue 1, 2007, Pages 101-114

  Atienzar, Franck ^a   Gerets, Helga ^a   Dufrane, Simon ^a   Tilmant, Karen ^a   Cornet, Miranda ^a   Dhalluin, Stephane ^a   Ruty, Bernard ^a   Rose, Geoffrey ^a   Canning, Michael ^a  

^a UCB PHARMA   (Belgium)

Author keywords

Biomarkers; Gene expression; HepG2 cells; Phospholipidosis; Screening activities

Indexed keywords

1 NAPHTHYL ISOTHIOCYANATE; 1,4 BIS(2 CHLOROBENZYLAMINOMETHYL)CYCLOHEXANE; AMIODARONE; AMITRIPTYLINE; BETA NAPHTHOFLAVONE; BIOLOGICAL MARKER; CHLORPROMAZINE; CLOMIPRAMINE; CLOZAPINE; DISOPYRAMIDE; ERYTHROMYCIN; FLECAINIDE; FLUOXETINE; HALOPERIDOL; ISONIAZID; KETOCONAZOLE; OFLOXACIN; PARACETAMOL; PERHEXILINE; PHENOBARBITAL; PROCAINAMIDE; SOTALOL; TAMOXIFEN; TETRACYCLINE; THIORIDAZINE; VALPROIC ACID; ZIMELDINE;

ARTICLE; CELL STRAIN HEPG2; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION COEFFICIENT; GENE EXPRESSION; HUMAN; HUMAN CELL; LIPIDOSIS; POLYMERASE CHAIN REACTION; QUANTITATIVE ANALYSIS; SCREENING TEST; VALIDATION PROCESS;

BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; GENE EXPRESSION PROFILING; HEPATOCYTES; HUMANS; LIPIDOSES; LIVER NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHARMACEUTICAL PREPARATIONS; PHOSPHOLIPIDS; POLYMERASE CHAIN REACTION; REPRODUCIBILITY OF RESULTS; RNA, MESSENGER; TOXICITY TESTS; UP-REGULATION;

EID: 33847259816     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfl184     Document Type: Article

References (40)

1. Argast, M., and Beck, C. F. (1984). Tetracycline diffusion through phospholipid bilayers and binding to phospholipids. Antimicrob. Agents Chemother. 26, 263-265.
2. Bockhardt, H., and Lullmann-Rauch, R. (1980). Zimelidine-induced lipidosis in rats. Acta Pharmacol. Toxicol. (Copenh) 47, 45-48.
3. Camus, P., and Mehendale, H. M. (1986). Pulmonary sequestration of amiodarone and desethylamiodarone. J. Pharmacol. Exp. Ther. 237, 867-873.
4. Cantor, J. O., Keller, S., Mandl, I., and Turino, G. M. (1987). Increased synthesis of elastin in amiodarone-induced pulmonary fibrosis. J. Lab. Clin. Med. 109, 480-485.
5. Casartelli, A., Bonato, M., Cristofori, P., Crivellente, F., Dal Negro, G., Masotto, I., Mutinelli, C.,Valko, K., and Bonfante, V. (2003). A cell-based approach for the early assessment of the phospholipidogenic potential in pharmaceutical research and drug development. Cell Biol. Toxicol. 19, 161-176.
6. Chisholm, J. W., Nation, P., Dolphin, P. J., and Agellon L. B. (1999). High plasma cholesterol in drug-induced cholestasis is associated with enhanced hepatic cholesterol synthesis. Am. J. Physiol. 276, 1165-1173.
7. de Longueville, F., Atienzar, F. A., Marcq, L., Dufrane, S., Evrard, S., Wouters, L., Leroux, F., Bertholet, V., Gerin, B., Whomsley, R., et al. (2003). Use of a low-density microarray for studying gene expression patterns induced by hepatotoxicants on primary cultures of rat hepatocytes. Toxicol. Sci. 75, 378-392.
8. Drenckhahn, D., Kleine, L., and Lullmann-Rauch, R. (1976). Lysosomal alterations in cultured macrophages exposed to anorexigenic and psychotropic drugs. Lab. Invest. 35, 116-123.
9. Gonzalez-Rothi, R. J., Zander, D. S., and Ros, P. R. (1995). Fluoxetine hydrochloride (Prozac)-induced pulmonary disease. Chest 107, 1763-1765.
10. Gum, R. J., Hickman, D., Fagerland, J. A., Heindel, M. A., Gagne, G. D., Schmidt, J. M., Michaelides, M. R., Davidsen, S. K., and Ulrich, R. G. (2001). Analysis of two matrix metalloproteinase inhibitors and their metabolites for induction of phospholipidosis in rat and human hepatocytes. Biochem. Pharmacol. 62, 1661-1673.
11. Iwasa, F., Galbraith, R. A., and Sassa, S. (1990). Phenotypic variation in human HepG2 hepatoma cells: Alterations in cell growth, plasma protein synthesis and heme pathway enzymes. Int. J. Biochem. 22, 303-310.
12. Joshi, U. M., Rao, P., Kodavanti, S., Lockard, V. G., and Mehendale, H. M. (1989). Fluorescence studies on binding of amphiphilic drugs to isolated lamellar bodies: Relevance to phospholipidosis. Biochim. Biophys. Acta 1004, 309-320.
13. Kasahara, T., Tomita, K., Murano, H., Harada, T., Tsubakimoto, K., Ogihara, T., Ohnishi, S., and Kakinuma, C. (2006). Establishment of an in vitro high-throughput screening assay for detecting phospholipidosis-inducing potential. Toxicol. Sci. 90, 133-141.
14. Kodavanti, U. P., and Mehendale, H. M. (1990). Cationic amphiphilic drugs and phospholipid storage disorder. Pharmacol. Rev. 42, 327-354.
15. Laurent, G, Kishore, B. K., and Tulkens P. M. (1990). Aminoglycoside-induced renal phospholipidosis and nephrotoxicity. Biochem. Pharmacol. 40, 2383-2392.
16. Lullmann-Rauch, R. (1974). Lipidosis-like ultrastructural alterations in rat lymph nodes after treatment with tricyclic antidepressants or neuroleptics. Naunyn. Schmiedebergs Arch. Pharmacol. 286, 165-179.
17. Lullmann-Rauch, R. (1979). Drug-induced lysosomal storage disorders. Font. Biol. 48, 49-130.
18. Lullmann, H., Lullmann-Rauch, R., and Wassermann, O. (1978). Lipidosis induced by amphiphilic cationic drugs. Biochem. Pharmacol. 27, 1103-1108.
19. Montenez, J. P., Van Bambeke, F., Piret, J., Brasseur, R., Tulkens, P. M., and Mingeot-Leclercq M. P. (1999). Interactions of macrolide antibiotics (Erythromycin A, roxithromycin, erythromycylamine [Dirithromycin], and azithromycin) with phospholipids: Computer-aided conformational analysis and studies on acellular and cell culture models. Toxicol. Appl. Pharmacol. 156, 129-140.
20. Morelli, J. K., Buehrle, M., Pognan, F., Barone, L. R., Fieles, W., and Ciaccio, P. J. (2006). Validation of an in vitro screen for phospholipidosis using a high-content biology platform. Cell Biol. Toxicol. 22, 15-27.
21. Pakuts, A. P., Parks, R. J., Paul, C. J., Bujaki, S. J., and Mueller, R. W. (1990). Ketoconazole-induced hepatic lysosomal phospholipidosis: The effect of concurrent barbiturate treatment. Res. Commun. Chem. Pathol. Pharmacol. 67, 55-62.
22. Pessayre, D., Bichara, M., Degott, C., Potet, F., Benhamou, J. P., and Feldmann, G. (1979). Perhexiline maleate-induced cirrhosis. Gastroenterology 76, 170-177.
23. Ploemen, J. P., Kelder, J., Hafmans, T., van de Sandt, H., van Burgsteden, J. A., Saleminki, P. J., and van Esch, E. (2004). Use of physicochemical calculation of pKa and CLogP to predict phospholipidosis-inducing potential: A case study with structurally related piperazines. Exp. Toxicol. Pathol. 55, 347-355.
24. Reasor, M. J. (1989). A review of the biology and toxicologic implications of the induction of lysosomal lamellar bodies by drugs. Toxicol. Appl. Pharmacol. 97, 47-56.
25. Reasor, M.J., and Davis, M. E. (1985). Prevention of chlorphentermine-induced pulmonary phospholipidosis in rats by phenobarbital. Drug Metab. Dispos. 13, 192-196.
26. Reasor, M. J., Hastings, K. L., and Ulrich, R. G. (2006). Drug-induced phospholipidosis: Issues and future directions. Expert Opin. Drug Saf. 5, 567-583.
27. Reasor, M. J., and Kacew, S. (2001). Drug-induced phospholipidosis: Are there functional consequences? Exp. Biol. Med. 226, 825-830.
28. Samadian, T., Dehpour, A. R, Amini, S., and Nouhnejad, P. (1993). Inhibition of gentamicin-induced nephrotoxicity by lithium in rat. Histol. Histopathol. 8, 39-47.
29. Sawada, H., Takami, K., and Asahi, S. (2005). A toxicogenomic approach to drug-induced phospholipidosis: Analysis of its induction mechanism and establishment of a novel in vitro screening system. Toxicol. Sci. 83, 282-292.
30. Sawada, H., Taniguchi, K., and Takami, K. (2006). Improved toxicogenomic screening for drug-induced phospholipidosis using a multiplexed quantitative gene expression Array Plate assay. Toxicol. In Vitro 20, 1506-1513.
31. Schneider, P., Korolenko, T. A., and Busch, U. (1997). A review of drug-induced lysosomal disorders of the liver in man and laboratory animals. Microsc. Res. Tech. 36, 253-275.
32. Tang, W., Borel, A. G., Fujimiya, T., and Abbott, F. S. (1995). Fluorinated analogues as mechanistic probes in valproic acid hepatotoxicity: Hepatic microvesicular steatosis and glutathione status.Chem. Res. Toxicol. 8, 671-682.
33. Ulrich, R. G., Kilgore, K. S., Sun, E. L., Cramer, C. T., and Ginsburg, L. C. (1991). An in vitro fluorescent assay for the detection of drug-induced cytoplasmic lamellar bodies. Toxicol. Methods 1, 89-105.
34. Van Pelt, J. F., Decorte, R., Yap, P. S., and Fevery, J. (2003). Identification of HepG2 variant cell lines by short tandem repeat (STR) analysis. Mol. Cell. Biochem. 243, 49-54.
35. Waters, E., Wang, J. H., Redmond, H. P., Wu, Q. D., Kay, E., and Bouchier-Hayes, D. (2001). Role of taurine in preventing acetaminophen-induced hepatic injury in the rat. Am. J. Physiol. Gastrointest. Liver Physiol. 280, 1274-1279.
36. Whitehouse, L. W., Menzies, A., Mueller, R., and Pontefract, R. (1994). Ketoconazole-induced hepatic phospholipidosis in the mouse and its association with de-N-acetyl ketoconazole. Toxicology 94, 81-95.
37. Xia, Z., Ying, G., Hansson, A. L., Karlsson, H., Xie, Y., Bergstrand, A., DePierre, J. W., and Nassberger, L. (2000). Antidepressant-induced lipidosis with special reference to tricyclic compounds. Prog. Neurobiol. 60, 501-512.
38. Yoshida, Y., Arimoto, K., Sato, M., Sakuragawa, N., Arima, M., and Satoyoshi, E. (1985). Reduction of acid sphingomyelinase activity in human fibroblasts induced by AY-9944 and other cationic amphiphilic drugs. J. Biochem. (Tokyo) 98, 1669-1679.
39. Young, R. A., and Mehendale, H. M. (1987). Effect of cytochrome P-450 and flavin-containing monooxygenase modifying factors on the in vitro metabolism of amiodarone by rat and rabbit. Drug Metab. Dispos. 15, 511-517.
40. Zhu, Y., Traub, L. M. and Kornfeld, S. (1999). High-affinity binding of the AP-1 adaptor complex to trans-golgi network membranes devoid of mannose 6-phosphate receptors. Mol. Biol. Cell 10, 537-549.